EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Dronedarone provides effective early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET 4 criteria

Paulus Kirchhof iD, A John Camm iD, Harry J G M Crijns iD, Jonathan P Piccini iD, Christian Torp-Pedersen iD, David S McKindley iD, Mattias Wieloch iD, Stefan H Hohnloser iD

Europace · 2025

DOI: 10.1093/europace/euaf080 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Europace, 2025. Verfasst von Paulus Kirchhof und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Anti-Arrhythmia Agents, Atrial Fibrillation, Atrial Flutter, Dronedarone. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This post-hoc analysis of the ATHENA trial assessed whether dronedarone (400 mg twice daily) improved cardiovascular outcomes compared with placebo in patients with early atrial fibrillation/atrial flutter (AF) and cardiovascular comorbidities, based on EAST-AFNET 4 inclusion criteria and outcomes. Methods and results The co-primary outcomes were (i) a composite of cardiovascular death, stroke, or hospitalisation due to worsening of heart failure (HF) or acute coronary syndrome (ACS) and (ii) nights spent in hospital per year. Sinus rhythm (SR) at 12 months was a secondary outcome. The primary safety outcome was a composite of death, stroke, or pre-specified serious adverse events of special interest (AESIs) related to rhythm control therapy. 1810 patients with early AF were identified. Patients receiving dronedarone had fewer deaths from cardiovascular causes, strokes, or hospitalisations due to worsening of HF or ACS compared with patients receiving placebo [dronedarone (n = 924), 87 patients with ≥1 event; placebo (n = 886), 117 patients with ≥1 event; hazard ratio 0.71; 95% confidence interval 0.54–0.94; P = 0.014]. Number of nights spent in hospital did not differ between treatment groups. More patients receiving dronedarone (69.2%) were in SR at 12 months compared with placebo (60.8%). Primary safety events comprising death, stroke, or pre-specified serious AESIs related to rhythm control therapy were not different (dronedarone vs. placebo: 60 vs. 71 patients with ≥1 event).

Conclusion

These data support the use of dronedarone for early rhythm control therapy in selected patients with early AF.

Trial registration

ATHENA: ClinicalTrials.gov identifier NCT00174785. EAST-AFNET 4: ClinicalTrials.gov identifier NCT01288352.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Arrhythmia AgentsAtrial FibrillationAtrial FlutterDronedaroneHeart RateAgedFemaleHumansMaleMiddle AgedAcute Coronary SyndromeComorbidityDouble-Blind MethodHeart FailureHospitalizationRisk FactorsStrokeTime FactorsTreatment Outcome

Stichwörter der Autor:innen

Atrial fibrillationAtrial flutterDronedaroneEarly rhythm control

Substanzen

Anti-Arrhythmia AgentsDronedarone

Autor:innen und Institutionen

  • Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • German Center for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Germany.
  • Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
  • Institute of Molecular and Clinical Sciences, St. George's University of London, London, UK.
  • Maastricht University Medical Centre and Cardiovascular Research Institute, Maastricht, The Netherlands.
  • Duke University Medical Center and the Duke Clinical Research Institute, Durham, NC, USA.

ORCID-Profile: Paulus Kirchhof, A John Camm, Harry J G M Crijns, Jonathan P Piccini, Christian Torp-Pedersen, David S McKindley, Mattias Wieloch, Stefan H Hohnloser

Förderung

  • Sanofi

Zitieren

APA

Kirchhof, P., Camm, A. J., Crijns, H. J. G. M., Piccini, J. P., Torp-Pedersen, C., McKindley, D. S., Wieloch, M., & Hohnloser, S. H. (2025). Dronedarone provides effective early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET 4 criteria. Europace. https://doi.org/10.1093/europace/euaf080

Vancouver

Kirchhof P, Camm AJ, Crijns HJGM, Piccini JP, Torp-Pedersen C, McKindley DS, et al. Dronedarone provides effective early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET 4 criteria. Europace. 2025. doi:10.1093/europace/euaf080

BibTeX
@article{Kirchhof2025,
  author = {Kirchhof, Paulus and Camm, A John and Crijns, Harry J G M and Piccini, Jonathan P and Torp-Pedersen, Christian and McKindley, David S and Wieloch, Mattias and Hohnloser, Stefan H},
  title = {Dronedarone provides effective early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET 4 criteria},
  journal = {Europace},
  year = {2025},
  doi = {10.1093/europace/euaf080}
}
Kostenlos starten →